Previous 10 | Next 10 |
Invitae (NYSE:NVTA) has gained ~9.2% in post-market trading amid reports that Exact Sciences (NASDAQ:EXAS) has approached the company for a possible merger. Companies are not in active talks, and if a deal materializes, it could be an all-stock deal with a low premium, Bloomberg rep...
Shares of Invitae (NYSE: NVTA) were up 9.4% as of 12:50 p.m. EDT Wednesday after the company delivered an upbeat earnings report and raised its guidance. Image source: Getty Images. The genetic testing company posted 152% year-over-year revenue growth in the second quarter a...
Image source: The Motley Fool. Invitae (NYSE: NVTA) Q2 2021 Earnings Call Aug 03, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Invitae (NVTA) Q2 2021 Earnings Call Transcript
The following slide deck was published by Invitae Corporation in conjunction with their 2021 Q2 earnings call. For further details see: Invitae Corporation 2021 Q2 - Results - Earnings Call Presentation
Invitae Corporation (NVTA) Q2 2021 Earnings Conference Call August 3, 2021 4:30 PM ET Company Participants Laura D'Angelo - Head, Investor Relations Sean George - Chief Executive Officer and Co-Founder Roxi Wen - Chief Financial Officer Ken Knight - Chief Operating Officer Shelly Guyer - Sust...
Invitae (NYSE:NVTA) shares rise nearly 2% post market after reporting second-quarter results that beat Wall Street estimates, and raised its revenue forecast for the year. The company increased its guidance of revenue between $475-$500 million in 2021 vs consensus of $462.61M. ...
Invitae (NYSE:NVTA): Q2 Non-GAAP EPS of -$0.85; GAAP EPS of -$0.64 beats by $0.06. Revenue of $116.31M (+151.8% Y/Y) beats by $6.57M. Reported billable volume of 287,000 in the quarter, a 154% increase compared to 113,000 in the same period in 2020 Reported preliminary average cost per billab...
Invitae Reports $116.3 Million in Revenue Driven by 287,000 in Billable Volume in Second Quarter of 2021 -- Increased quarterly revenue by 152% year-over-year -- -- Increases guidance of revenue between $475-$500 million in 2021 -- -- Hosting conference call and webcast ...
The healthcare industry’s relatively inelastic demand and its crucial role in fighting the COVID-19 pandemic will likely make it a popular choice for investors seeking to hedge their portfolios against a possible market correction. Given genomics’ and technology-based healthcare...
Volpara Collaborates With Invitae Corporation, Leading Genetics Company Collaboration Expands Access to Genetic Testing and Risk Assessment Capabilities Available through Volpara's Breast Health Platform PR Newswire SEATTLE , July 22, 2021 /PRNewswire/ -- ...
News, Short Squeeze, Breakout and More Instantly...
Labcorp Announces Winning Bid for Select Assets of Invitae PR Newswire Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 ...
Invitae Enters into Agreement with Labcorp for Sale of Business PR Newswire – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantial...
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance PR Newswire – Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewsw...